Terms: = Lymphoma AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b
138 results:
1. B-cell ALL with SOX11 gene amplification associates with a worse outcome.
Angelakakis G; Varkhedi M; Dabkowski TR; Diaz MJ; Yeagley M; Blanck G
Cell Cycle; 2024 Jan; 23(1):36-42. PubMed ID: 38350028
[TBL] [Abstract] [Full Text] [Related]
2. The novel TERF2::pdgfrb fusion gene enhances tumorigenesis via pdgfrb/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
[TBL] [Abstract] [Full Text] [Related]
3. Myeloid and lymphoid neoplasm with novel complex translocation: unusual case report with T-lymphoblastic lymphoma, myeloid hyperplasia, eosinophilia, basophilia, and t(1;8;10)( (p31;q24;q11.2).
Aljabry MS
J Hematop; 2023 Mar; 16(1):27-31. PubMed ID: 38175368
[TBL] [Abstract] [Full Text] [Related]
4. A novel subclonal rearrangement of the STRN3::pdgfrb gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects.
Wang Z; Liu T; Liu W; Gao X; Wan L; Qiu S; Song Y; Gu R; Tian Z; Wang M; Wang J; Mi Y; Wei S
Cancer Gene Ther; 2023 Nov; 30(11):1471-1484. PubMed ID: 37550570
[TBL] [Abstract] [Full Text] [Related]
5. Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children's Cancer Group study ALL-2015.
Liu K; Shao J; Cai J; Tang J; Shen S; Xu F; Ren Y; Zhang A; Tian X; Lu X; Hu S; Hu Q; Jiang H; Zhou F; Liang C; Leung AWK; Zhai X; Li C; Fang Y; Wang Z; Wen L; Yang H; Wang N; Jiang H
Ann Hematol; 2023 Dec; 102(12):3431-3444. PubMed ID: 37550503
[TBL] [Abstract] [Full Text] [Related]
6. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.
Metzgeroth G; Steiner L; Naumann N; Lübke J; Kreil S; Fabarius A; Haferlach C; Haferlach T; Hofmann WK; Cross NCP; Schwaab J; Reiter A
Leukemia; 2023 Sep; 37(9):1860-1867. PubMed ID: 37454239
[TBL] [Abstract] [Full Text] [Related]
7. SHIP1 Is Present but Strongly Downregulated in T-ALL, and after Restoration Suppresses Leukemia Growth in a T-ALL Xenotransplantation Mouse Model.
Ehm P; Rietow R; Wegner W; Bußmann L; Kriegs M; Dierck K; Horn S; Streichert T; Horstmann M; Jücker M
Cells; 2023 Jul; 12(13):. PubMed ID: 37443832
[TBL] [Abstract] [Full Text] [Related]
8. Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
Moosburner M; Alibegovic L; Hasselmann K; Gaiderov A; Hildebrand J; Philippou-Massier J; Blum H; Fischer L; Dreyling M; Silkenstedt E
Hematol Oncol; 2023 Dec; 41(5):858-868. PubMed ID: 37300279
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase.
Gao T; Huang J; Yin H; Huang J; Xie J; Zhou T; Fan W; Yang X; Gao G; Li Z
Cell Death Dis; 2023 May; 14(5):316. PubMed ID: 37160920
[TBL] [Abstract] [Full Text] [Related]
10. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract] [Full Text] [Related]
11. [Prognostic analysis of children with Philadelphia chromosome-like acute lymphoblastic leukemia common genes].
Hu WD; Li B; Su SF; Liu YF; Liu W; Zhang WL; Zuo WL; Yu RH
Zhonghua Er Ke Za Zhi; 2023 May; 61(5):446-452. PubMed ID: 37096265
[No Abstract] [Full Text] [Related]
12. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
Preobrazhenskaya EV; Suleymanova AM; Bizin IV; Zagrebin FA; Romanko AA; Saitova ES; Mulkidzhan RS; Imyanitov EN
Histopathology; 2023 Jul; 83(1):109-115. PubMed ID: 37071060
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell lymphoma Patients.
Wang H; Lin Y; Li Z; Wu Y; Yang Z; Gao S; Lin F
Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649512
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y; Nguyen L; Lu CM; Wang E; Lauw MIS; Ball S; Dong N; Moscinski L; Chan O; Yun S; Sallman D; Sokol L; Shah B; Knepper T; Lancet J; Komrokji R; Padron E; Kuykendall A; Zhang L
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e150-e163. PubMed ID: 36624015
[TBL] [Abstract] [Full Text] [Related]
15. Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.
Venn NC; Huang L; Hovorková L; Muskovic W; Wong M; Law T; Heatley SL; Khaw SL; Revesz T; Dalla Pozza L; Shaw PJ; Fraser C; Moore AS; Cross S; Bendak K; Norris MD; Henderson MJ; White DL; Cowley MJ; Trahair TN; Zuna J; Sutton R
Br J Cancer; 2022 Sep; 127(5):908-915. PubMed ID: 35650277
[TBL] [Abstract] [Full Text] [Related]
16. Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/pdgfrA axis.
Arribas AJ; Napoli S; Cascione L; Sartori G; Barnabei L; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone-Pittau R; Di Veroli A; Stathis A; Cruciani G; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Haematologica; 2022 Nov; 107(11):2685-2697. PubMed ID: 35484662
[TBL] [Abstract] [Full Text] [Related]
17. Histopathologic and Molecular Characterization of Uterine Leiomyoma-like Inflammatory Myofibroblastic Tumor: Comparison to Molecular Subtypes of Uterine Leiomyoma.
Kuisma H; Jokinen V; Pasanen A; Heikinheimo O; Karhu A; Välimäki N; Aaltonen L; Bützow R
Am J Surg Pathol; 2022 Aug; 46(8):1126-1136. PubMed ID: 35426837
[TBL] [Abstract] [Full Text] [Related]
18. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.
Witte HM; Künstner A; Hertel N; Bernd HW; Bernard V; Stölting S; Merz H; von Bubnoff N; Busch H; Feller AC; Gebauer N
Blood Adv; 2022 Jan; 6(2):637-651. PubMed ID: 34714908
[TBL] [Abstract] [Full Text] [Related]
19. Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease.
Petinati NA; Shipounova IN; Fastova EA; Magomedova AU; Kravchenko SK; Chelysheva EY; Shukhov OA; Turkina AG; Sats NV; Drize NI; Parovichnikova EN; Savchenko VG
Bull Exp Biol Med; 2021 Aug; 171(4):553-558. PubMed ID: 34542753
[TBL] [Abstract] [Full Text] [Related]
20. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S
Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401
[TBL] [Abstract] [Full Text] [Related]
[Next]
